Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 May 19;20(1):234.
doi: 10.1186/s12872-020-01513-1.

Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway

Sarah Cook  1 , Laila A Hopstock  2 , Anne Elise Eggen  2 , Katie Bates  3   4 , Olena Iakunchykova  2 , Anna Kontsevaya  5 , Martin McKee  3 , Henrik Schirmer  6   7 , Michael Voevoda  8 , Alexander V Kudryavtsev  2   9 , Sofia Malyutina  8   10 , David A Leon  2   11
Affiliations
Comparative Study

Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway

Sarah Cook et al. BMC Cardiovasc Disord. .

Abstract

Background: Cardiovascular disease (CVD) mortality is substantially higher in Russia than in neighbouring Norway. We aimed to compare blood pressure- and lipid-lowering medication use and proportion meeting treatment targets between general population samples in the two countries in those with CVD and diabetes.

Methods: The study population was adults aged 40-69 years reporting a diagnosis of myocardial infarction (MI), stroke and/or diabetes participating in cross-sectional population-based studies in Russia (Know Your Heart (KYH) 2015-18 N = 626) and Norway (The Tromsø Study 2015-16 (Tromsø 7) N = 1353). Reported medications were coded according to the 2016 WHO Anatomical Therapeutic Chemical Classification system. Treatment targets were defined using the Joint European Societies guidelines for CVD prevention in clinical practice (2016).

Results: Age- and sex-standardized prevalence of use of lipid-lowering medications was higher in Tromsø 7 for all three conditions with a disproportionately large difference in those reporting MI (+ 48% (95% CI 39, 57%)). Proportion meeting treatment targets for LDL cholesterol was poor in both studies (age- and sex-standardized prevalence of control KYH vs Tromsø 7: MI 5.1% vs 10.1%; stroke 11.6% vs 5.8%; diabetes 24.9% vs 23.3%). Use of antihypertensive medication was higher in KYH for stroke (+ 40% (95% CI 30, 50%)) and diabetes (+ 27% (95% CI 19, 34%)) groups but approximately equal for the MI group (- 1% (95% CI -1, 1%)). Proportion meeting blood pressure targets was lower in KYH vs Tromsø 7 (MI 51.8% vs 76.3%; stroke 49.5% vs 69.6%; diabetes 51.9% vs 63.9%).

Conclusions: We identified different patterns of medication use in people with CVD and diabetes. However despite higher use of lipid-lowering medication in the Norwegian study treatment to target for total cholesterol was poor in both Russian and Norwegian studies. In contrast we found higher levels of use of antihypertensive medications in the Russian study but also that less participants met treatment targets for blood pressure. Further work should investigate what factors are responsible for this seeming paradox and how management of modifiable risk factors for secondary prevention could be improved.

Keywords: Diabetes; Myocardial infarction; Norway; Russian Federation; Secondary prevention; Stroke.

PubMed Disclaimer

Conflict of interest statement

Henrik Schirmer has received an unrestricted research grant from Astra Zeneca and lecture fees from Astra Zeneca, MSD, Novartis and Sanofi Aventis.

Figures

Fig. 1
Fig. 1
Age- and sex-standardised prevalence of the use of lipid-lowering medications in KYH and Tromsø 7 in participants reporting MI, stroke or diabetes
Fig. 2
Fig. 2
Age- and sex-standardised prevalence of the use of antihypertensive medications in KYH and Tromsø 7 in participants reporting MI, stroke or diabetes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Global Health Observatory. World Health Organisation. Total NCD Mortality Data by country Geneva: Available online http://apps.who.int/gho/data/node.main. A860?lang=en 2017 [.
    1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232–3245. doi: 10.1093/eurheartj/ehw334. - DOI - PubMed
    1. World Health Organisation. WHO Mortality Database. Available online http://www.who.int/healthinfo/mortality_data/en/ access date 07/12/2017; 2017.
    1. Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636–648. doi: 10.1177/2047487315569401. - DOI - PubMed
    1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J. 2016;37(29):2315–2381. doi: 10.1093/eurheartj/ehw106. - DOI - PMC - PubMed

Publication types

MeSH terms